2 Majority of patients were treated with standard of care 1,2,n,o Summary of medication at baseline (N=3533) 1,2 Select CV and CKD baseline characteristics (N=3533) 1,2 n At baseline patients in FLOW were receiving standard-of-care background therapy, including a maximum tolerated label dose of a RAAS-blocking agent including an ACE inhibitor or an ARB, unless such treatment was contraindicated or not tolerated
Constipation: While some patients experience diarrhea, others may find that digestion slows too much, leading to constipation
Foundayo, approved in 2026, offers unmatched dosing flexibility, being free of food and water restrictions
Cellular Longevity often runs alongside GLP1 or Tesamorelin programs, performance peptides, and KBeauty facials to synchronize internal aging pathways with body composition and skin health
Buyers should ask any compounded GLP-1 platform about their specific compounding pharmacy's legal compliance framework under current FDA guidance
tirzepatide GLP-1 + GIP